Substance / Medication

Mazindol

Overview

Active Ingredient
mazindol
RxNorm CUI
6664

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

426 trials linked to this intervention

426
Total Trials
122
Recruiting
109
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Global self-esteem and degree of overweight/obesity: are they linked in the adult population? A systematic review and meta-analysis.
Moyon Lisa, Gonthier Corentin, Brun Laurent et al. · Psychol Health · 2026
PMID: 39318099Meta-Analysis
The impact of obesity on radiographic and clinical outcomes following adult spinal deformity surgery-a systematic review and meta-analysis.
Pajak Anthony, Dekhne Mihir, Lui Adrian T H et al. · Spine J · 2026
PMID: 40639618Meta-Analysis
Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients.
Lucchetta Rosa Camila, Riveros Bruno Salgado, Pontarolo Roberto et al. · Clinics (Sao Paulo) · 2017
PMID: 28591345Meta-AnalysisFull text (PMC)
Metformin improves the weight reduction effect of mazindol in prediabetic obese Mexican subjects.
Arguelles-Tello Federico Alberto, Kammar-García Ashuin, Trejo-Jasso Cristian Adolfo et al. · Int J Clin Pharmacol Ther · 2022
PMID: 35770520RCTFull text (PMC)
Pharmacokinetics study of mazindol in plasma, oral fluid, and urine of volunteers.
de Oliveira Marcella Herbstrith, Ferreira Pâmela Cristina Lukasewicz, Carlos Graciela et al. · Eur J Clin Pharmacol · 2016
PMID: 27066959Trial
Pilot Phase II study of mazindol in children with attention deficit/hyperactivity disorder.
Konofal Eric, Zhao Wei, Laouénan Cédric et al. · Drug Des Devel Ther · 2014
PMID: 25525331TrialFull text (PMC)
Mazindol in narcolepsy and idiopathic and symptomatic hypersomnia refractory to stimulants: a long-term chart review.
Nittur Nandini, Konofal Eric, Dauvilliers Yves et al. · Sleep Med · 2013
PMID: 23036267Trial
Mazindol treatment of negative symptoms.
Carpenter W T, Breier A, Buchanan R W et al. · Neuropsychopharmacology · 2000
PMID: 10989263Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Mazindol (substance)
SNOMED CT
387232005
UMLS CUI
C0024977
RxNorm CUI
6664

Clinical Data

This intervention maps to 11 entities in the Ltrl knowledge graph.

3
Conditions
3
Biomarkers
3
Specialists
0
Symptoms
426
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.

Mazindol: Uses, Evidence & Side Effects | Ltrl